Could PGC-1α hold the key to longevity?
Endurance Bio, spun out of Tranquis Therapeutics and building on Stanford research, is advancing a PGC-1α-targeted small molecule program (T‑168) toward a Phase 2 Parkinson’s trial within a biomarker-rich platform led by Professor Charalampos Tzoulis. Preclinical data indicate dual mitochondrial and lysosomal mechanisms with potential applicability across neurodegeneration, sarcopenia, and metabolic aging; a second molecule is in IND-enabling studies and a library of analogues is ready for exploration. The company aims to validate metabolic and lysosomal biomarkers in humans to de-risk expansion into ALS and other age-related indications.
Why it mattersPhase 2 Parkinson's trial of PGC-1α activator T-168 warrants prioritizing mitochondrial and lysosomal biomarkers in trials.